ACADIA Pharmaceuticals Inc To Discuss Complete Response Letter from U.S. FDA for Supplemental New Drug Application Transcript
Good day, ladies and gentlemen, and welcome to ACADIA Pharmaceuticals conference call. My name is Catherine, and I'll be your coordinator for today. (Operator Instructions)
I would now like to turn the presentation over to Mark Johnson, Vice President of Investor Relations at ACADIA. Please proceed.
Thank you, Catherine. Joining me on today's call from ACADIA are Steve Davis, our Chief Executive Officer; and Dr. Serge Stankovic, our President, who will provide some prepared remarks before opening the call for your questions. Also joining us today is Elena Ridloff, our Chief Financial Officer.
I would also like to point out that we are using supplement slides, which are available on the Events and Presentations section of our website. Please turn to Slide 2.
Before we proceed, I would first like to remind you that during our call today, we'll be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
